Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01697657
Registration number
NCT01697657
Ethics application status
Date submitted
28/09/2012
Date registered
2/10/2012
Date last updated
27/01/2017
Titles & IDs
Public title
Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes
Query!
Scientific title
A Randomised, Open Label, Cross-over, Multi-centre, Multinational Trial Comparing the Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir and NPH Insulin in Well Controlled Subjects With Type 1 Diabetes on a Basal-bolus Regimen
Query!
Secondary ID [1]
0
0
NN304-1375
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes
0
0
Query!
Diabetes Mellitus, Type 1
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - insulin detemir
Treatment: Drugs - insulin NPH
Treatment: Drugs - insulin aspart
Experimental: Detemir -
Active Comparator: NPH -
Treatment: Drugs: insulin detemir
Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Treatment: Drugs: insulin NPH
Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Treatment: Drugs: insulin aspart
Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of total self-recorded hypoglycaemic episodes
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
Incidence of total major hypoglycaemic episodes
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [2]
0
0
HbA1c (glycosylated haemoglobin)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [3]
0
0
8-point plasma glucose profiles
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Secondary outcome [4]
0
0
Serum glucose profiles
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Query!
Secondary outcome [5]
0
0
72-hours glucose profile
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Query!
Secondary outcome [6]
0
0
Within-subject variation in home-measured fasting plasma glucose
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Query!
Secondary outcome [7]
0
0
Incidence of adverse events
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Query!
Eligibility
Key inclusion criteria
- Type 1 diabetes
- Fasting c-peptide below lower limit of normal fasting range
- Duration of type 1 diabetes for at least 12 months
- Current treatment: Basal - bolus regimen for at least 4 months with intermediate or
long-acting insulin once, twice or three times daily as basal insulin and 3-4 premeal
insulin aspart or lispro injections
- HbA1c maximum 9.0% (using Biorad Variant method)
- Able and willing to perform self-monitoring of blood glucose
- Basal insulin requirement at least 30% of the total daily insulin dose
- BMI (body Mass Index) maximum 35 kg/m^2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Proliferative retinopathy or maculopathy requiring acute treatment
- Total daily insulin dose above 1.4 IU/kg/day
- Known unawareness of hypoglycaemia
- Impaired hepatic function
- Impaired renal function
- Cardiac problems
- Uncontrolled, treated/untreated hypertension
- Known or suspected allergy to trial product or related products
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2001
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2002
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
131
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Novo Nordisk Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Novo Nordisk Investigational Site - Ashford
Query!
Recruitment hospital [3]
0
0
Novo Nordisk Investigational Site - Box Hill
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
5035 - Ashford
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment outside Australia
Country [1]
0
0
Croatia
Query!
State/province [1]
0
0
Zagreb
Query!
Country [2]
0
0
Denmark
Query!
State/province [2]
0
0
Køge
Query!
Country [3]
0
0
Denmark
Query!
State/province [3]
0
0
Århus C
Query!
Country [4]
0
0
Italy
Query!
State/province [4]
0
0
Citta' Di Castello
Query!
Country [5]
0
0
Italy
Query!
State/province [5]
0
0
Perugia
Query!
Country [6]
0
0
South Africa
Query!
State/province [6]
0
0
Western Cape
Query!
Country [7]
0
0
Sweden
Query!
State/province [7]
0
0
Linköping
Query!
Country [8]
0
0
Sweden
Query!
State/province [8]
0
0
Trelleborg
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novo Nordisk A/S
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This trial is conducted in Africa, Europe and Oceania. The aim of this trial is to
investigate whether insulin detemir combined with insulin aspart compared to NPH insulin
combined with insulin aspart could reduce the frequency of hypoglycaemic episodes whilst
maintaining the same degree of glycaemic control subjects with type 1 diabetes.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01697657
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Global Clinical Registry (GCR, 1452)
Query!
Address
0
0
Novo Nordisk A/S
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01697657
Download to PDF